申请人:SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
公开号:EP0663210A2
公开(公告)日:1995-07-19
Use of a compound of formula (1) or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating a disease cause by a tumor necrosis factor :
wherein R1 represent a hydrogen atom, an alkyl group, an alkenyl group, an acyl group or a group of formula:
wherein R' represents a halogen atom, a hydroxyl group, an alkoxy group, an alkylthio group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, a cyano group, an amino group, an alkylamino group, a dialkylamino group, a cycloalkyl group, a heterocyclic group, an aromatic group or an aromatic heterocyclic group ; X1 represents a carbonyl group or a methylene group ; and k represents 0 or an integer of 1 to 5, with the proviso that when X1 is a carbonyl group and R7 is a hydroxyl group, or when X1 is a methylene group and R7 is a hydroxyl group, an amino group, an alkylamino group or a dialkylamino group, k represents an integer of 1 to 5 ; and, each of A and B independently represents a methylene group or a group of formula :
wherein each of R2 and R3 independently represents a hydrogen atom, an alkyl group, an alkoxycarbonyl group or a substituted alkyl group.
式(1)化合物或其药学上可接受的盐在制备预防或治疗由肿瘤坏死因子引起的疾病的药物组合物中的用途:
其中 R1 代表氢原子、烷基、烯基、酰基或式基团:
其中 R'代表卤原子、羟基、烷氧基、烷
硫基、羧基、烷氧羰基、芳氧羰基、
氰基、
氨基、烷基
氨基、二烷基
氨基、环烷基、杂环基、芳香基或芳香杂环基; X1 代表羰基或亚甲基;且 k 代表 0 或 1 至 5 的整数,但当 X1 为羰基且 R7 为羟基,或当 X1 为亚甲基且 R7 为羟基、
氨基、烷基
氨基或二烷基
氨基时,k 代表 1 至 5 的整数;且 A 和 B 各自独立地代表亚甲基或式......的基团:
其中 R2 和 R3 各自独立地代表氢原子、烷基、烷氧羰基或取代的烷基。